Certara (NASDAQ:CERT - Get Free Report) updated its FY 2025 earnings guidance on Wednesday. The company provided EPS guidance of 0.420-0.460 for the period, compared to the consensus EPS estimate of 0.500. The company issued revenue guidance of $415.0 million-$425.0 million, compared to the consensus revenue estimate of $422.4 million.
Analysts Set New Price Targets
A number of research firms have commented on CERT. William Blair reissued a "market perform" rating on shares of Certara in a report on Thursday. Barclays lifted their price target on Certara from $12.00 to $13.00 and gave the stock an "equal weight" rating in a research note on Friday. Stephens reaffirmed an "overweight" rating and set a $17.00 price target on shares of Certara in a research note on Thursday. Robert W. Baird cut their price target on Certara from $18.00 to $13.00 and set a "neutral" rating for the company in a research note on Tuesday, November 5th. Finally, TD Cowen initiated coverage on Certara in a research note on Thursday. They set a "buy" rating and a $16.00 price target for the company. Four research analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat, Certara currently has an average rating of "Moderate Buy" and an average target price of $15.83.
Get Our Latest Stock Report on Certara
Certara Price Performance
CERT stock traded down $0.42 during trading on Friday, hitting $11.98. The stock had a trading volume of 1,956,342 shares, compared to its average volume of 1,314,086. The company's 50 day moving average price is $12.45 and its two-hundred day moving average price is $11.63. Certara has a 1-year low of $9.41 and a 1-year high of $19.87. The stock has a market cap of $1.93 billion, a price-to-earnings ratio of -59.90, a price-to-earnings-growth ratio of 9.29 and a beta of 1.57. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.86 and a current ratio of 2.86.
Certara Company Profile
(
Get Free Report)
Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.
Read More
Before you consider Certara, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Certara wasn't on the list.
While Certara currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for March 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
